Lymphangiogenesis and its role in cancer

Histology and Histopathology

Volumn 20, Issue 1, 2005, Pages 283-298

  Al Rawi, Mahir A A ^a   Mansel, R E ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Lymphangiogenesis; LYVE 1; Podoplannin; Prox 1; VEGF C; VEGF D; VEGFR 3 and cancer metastasis

Indexed keywords

5' NUCLEOTIDASE; ADENOVIRUS VECTOR; BIOLOGICAL MARKER; DESMOPLAKIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HOMEODOMAIN PROTEIN; INTERLEUKIN 7; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; PODOPLANIN; POLYPEPTIDE; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

BASEMENT MEMBRANE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLORECTAL CANCER; DRUG TARGETING; ESOPHAGUS CANCER; GAP JUNCTION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA; METASTASIS POTENTIAL; MOLECULAR MECHANICS; NONHUMAN; PANCREAS CARCINOMA; PERICYTE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM; VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; WEIBEL PALADE BODY;

BIOLOGICAL MARKERS; GROWTH SUBSTANCES; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; NEOPLASMS;

ADENOVIRIDAE;

EID: 11144291058     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A., Alitalo K. and Stacker S. (1998). Vascular endothelial growth factor-D (VEGF-D) is a ligand for tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flk4). Proc.. Natl. Acad. Sci. USA. 95, 548-553.
2. Achen M.G., Williams R.A., Minekus M.P., Thornton G.E., Stenvers K., Rogers P.A., Lederman F., Roufail S. and Stacker S.A. (2001). Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol. 193, 147-54.
3. Akagi K., Ikeda Y., Miyazaki M., Abe T., Kinoshita J., Maehara Y. and Sugimachi K. (2000). Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83, 887-891.
4. Akagi Y., Liu W., Xie K., Zebrowski B., Shaheen R.M. and Ellis L.M. (1999). Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta. Br. J. Cancer 80, 1506-1511.
5. Alitalo K. (1997). Vascular endothelial growth factors and receptors involved in angiogenesis and lymphangiogenesis. Eur. J. Cancer 33, 1017-1017.
6. Alitalo K. and Carmeliet P. (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 1, 219-2127.
7. Al-Rawi M.A., Mansel R.E. and Jiang W.G. (2002). Interleukin-7 is a putative lymphangiogenic factor in endothelial cells. Breast Cancer Res. Treat. 76 (Supp 1), S166.
8. Al-Rawi M.A., Mansel R.E. and Jiang W.G. (2003). Interleukin-7 induced lymphangiogenesis is mediated by autocrine secretion of vascular endothelial growth factor-D (VEGF-D) in breast cancer. Breast Cancer Res. Treat. 82 (Supp 1), S134.
9. Al-Rawi M.A., Mansel R.E. and Jiang W. (2004a). Interleukin-7 (IL-7) upregulates the vascular endothelial factor - D (VEGF-D) in breast cancer cells and induces lymphangiogensis in vivo. Br. J. Surg. (in press).
10. Al-Rawi M.A., Mansel R.E. and Jiang W.G. (2004b). Contribution of the vascular endothelial growth factor - D (VEGF-D), in the Interleukin-7 (IL-7) - induced lymphangiogenesis. Proc AACR. 45, 2004.
11. Amioka T., Kitadai Y., Tanaka S., Haruma K., Yoshihara M., Yasui W. and Chayama K. (2002). Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer 38, 1413-1419.
12. Aukland K. and Reed R.K. (1993). Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 73, 1-78.
13. Auvinen M.I., Sihvo E.I., Ruohtula T., Salminen J.T., Koivistoinen A., Siivola P., Ronnholm R., Ramo J.O., Bergman M. and Salo J.A. (2002). Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J. Clin. Oncol. 20, 2971-2979.
14. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., Jones M. and Jackson D.G. (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph- specific receptor for hyaluronan. J. Cell Biol. 144, 789-801.
15. Beasley N.J., Prevo R., Banerji S., Leek R.D., Moore J., Van Trappen P., Cox G., Harris A.L. and Jackson D.G. (2002). Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 62, 1315-1320.
16. Bellomo D., Headrick J.P., Silins G.U., Paterson C.A., Thomas P.S., Gartside M., Mould A., Cahill M.M., Tonks I.D., Grimmond S.M., Townson S., Wells C., Little M., Cummings M.C., Hayward N.K. and Kay G.F. (2000). Mice lacking the vascular endothelial growth factor-B gene (VEGF-B) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86, E29-35.
17. Benjamin L., Hemo I. and E.K. (1998). A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598.
18. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Kowalski H. and Oberhuber G. (2000). Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res. 20, 2981-5.
19. Birner P., Schindl M., Obermair A., Breitenecker G., Kowalski H. and Oberhuber G. (2001). Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int. J. Cancer 95, 29-33.
20. Borg J.P., Delapeyriere O., Noguchi T., Rottapel R., Dubreuil P. and Birnbaum D. (1995). Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene 10, 973-84.
21. Breiteneder-Geleff S., Matsui K., Soleiman A., Meraner P., Poczewski H., Kalt R., Schaffner G. and Kerjaschki D. (1997). Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am. J. Pathol. 151, 1141-1152.
22. Breiteneder-Geleff S., Soleiman A., Kowalski H., Horvat R., Amman G., Kriehuber E., Diem K., Weninger W., Tschachler E., Alitalo K. and Kerjaschki D. (1999). Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 154, 385-394.
23. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M.A. and Bongarzone I. (1999). Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155, 1967-1976.
24. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L. and Alitalo K. (1998). Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 95, 14389-14394.
25. Carmeliet P. and Jain R. (2000). Angiogenisis in cancer and other diseases. Nature Med. 407, 249-257.
26. Carson-Walter E.B., Watkins D.N., Nanda A., Vogelstein B., Kinzler K.W. and St Croix B. (2001). Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61, 6649-6655.
27. Cunnick G.H., Jiang W.G., Gomez K.F. and Mansel R.E. (2001). Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem. Biophys. Res. Commun. 288, 1043-1046.
28. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., Ellwanger U., Garbe C., Mihm M.C. and Detmar M. (2003). Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162, 1951-1960.
29. Davies G., Mason M.D., Mansel R.E. and Jiang W.G. (2004). Expression of tumour endothelial markers in human breast cancer. Clin. Exp. Metast. (in press).
30. Dumont D., Jussila L., Taipale J., Lymboussaki A., Mustonen T., Pajusola K., Breitman M. and Alitalo K. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946-949.
31. Erhard H., Rietveldt F., Brocker E., De Waal R. and Ruiter D. (1996). Phenotype of normal cutaneous microvasculature immunoelectron microscopic observations with emphasis on the differences between blood vessels and lymphatics. J. Invest. Dermatol. 106, 135-140.
32. Eriksson U. and Alitalo K. (1999). Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol. 237, 41-57.
33. Evans A.L., Brice G., Sotirova V., Mortimer P., Beninson J., Burnand K., Rosbotham J., Child A. and Sarfarazi M. (1999). Mapping of primary congenital lymphedema to the 5q35.3 region. Am. J. Hum. Genet. 64, 547-555.
34. Ezaki T., Matsuno K., Fuji H., Hayashi N., Miyakawa K., Ohmori J. and Kotani M. (1990). A new approach for identification of rat lymphatic capillaries using a monoclonal antibody. Arch. Histol. Cytol. 53 Suppl., 77-86.
35. Fernandez E., La Vecchia C., Porta M., Negri E., Lucchini F. and Levi F. (1994). Trends in pancreatic cancer mortality in Europe, 1955-1989. Int. J. Cancer 57, 786-792.
36. Ferrell R.E., Levinson K.L., Esman J.H., Kimak M.A., Lawrence E.C., Barmada M.M. and Finegold D.N. (1998). Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum. Mol. Genet. 7, 2073-2078.
37. Fisher B. and Fisher E.R. (1966). Role of the lymphatic system in dissemination of tumour. Lymph. Lymphatic System 324.
38. Folkman J. (1956). Angiogenesis and tumour growth. New England J. Med. 333, 1757-1763.
39. Forbes J.F. (1997). The incidence of breast cancer: the global burden, public health considerations. Semin. Oncol. 24, S1-20-S1-35.
40. Fournier E., Blaikie P., Rosnet O., Margolis B., Birnbaum D. and Borg J.P. (1999). Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling. Oncogene 18, 507-514.
41. Fournier E., Dubreuil P., Birnbaum D. and Borg J.P. (1995). Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. Oncogene 11, 921-931.
42. Fraser J.R. and Laurent T.C. (1989). Turnover and metabolism of hyaluronan. Ciba Found. Symp. 143, 41-53; discussion 53-9, 281-285.
43. Fraser J.R., Kimpton W.G., Laurent T.C., Cahill R.N. and Vakakis N. (1988). Uptake and degradation of hyaluronan in lymphatic tissue. Biochem. J. 256, 153-158.
44. Furudoi A., Tanaka S., Haruma K., Kitadai Y., Yoshihara M., Chayama K. and Shimamoto F. (2002). Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 62, 157-166.
45. Galland F., Karamysheva A., Pebusque M.J., Borg J.P., Rottapel R., Dubreuil P., Rosnet O. and Birnbaum D. (1993). The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8, 1233-1240.
46. George M.L., Tutton M.G., Janssen F., Arnaout A., Abulafi A.M., Eccles S.A. and Swift R.I. (2001). VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 3, 420-427.
47. Gerber H.P., Mcmurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V. and Ferrara N. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1 /KDR activation. J. Biol. Chem. 273, 30336-30343.
48. Hanahan D. and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
49. Harrison R., Ewert A. and Folse D. (1986). Presence of Weible-Palade bodies in lymphatic endothelium of the cat. Lymphology 19, 170-171.
50. Hartveit F. (1990). Attenuated cells in breast stroma - the missing lymphatic- system of the breast, Histopathology 16, 533-543.
51. Ichikura T., Tomimatsu S., Ohkura E. and Mochizuki H. (2001). Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J. Surg. Oncol. 78, 132-137.
52. Jain R. (1987). Transport of molecules in the tumour interstitium: a review. Cancer Res. 47, 3039-3051.
53. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R. and Alitalo K. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425 [erratum Science 1997; 277, 463].
54. Jiang W.G., Parr C., Martin T.A., Davies G., Watkins G. and Mansel R.E. (2003). Is hepatocyte growth factor/scatter factor (HGF/SF) lymphangiogenic? Breast Cancer Res. Treat. 82, 272.
55. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O. and Alitalo K. (1998). A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 273, 6599-6602.
56. Joukov V.P.K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N. and Alitalo K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290-298 [erratum EMBO J. 1996; 15: 1751].
57. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claessonwelsh L., Cao Y.H., Saksela O., Kalkkinen N. and Alitalo K. (1997). Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898-3911.
58. Jussila L. and Alitalo K. (2002). Vascular growth factors and lymphangiogenesis. Physiol Rev. 82, 673-700.
59. Jussila L.V.R., Partanen T.A., Salven P., Heikkila P., Matikainen, M.R.R., Kaipainen A., Detmar M, Tschachler E, Alitalo R. and Alitalo K. (1998). Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58, 1599-1604.
60. Kabashima A., Maehara Y., Kakeji Y. and Sugimachi K. (2001). Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma. Oncology 60, 146-150.
61. Kaipainen A., Korhonen J., Mustonen T., Van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M. and Alitalo K. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92, 3566-3570.
62. Kaipainen A., Korhonen J., Pajusola K., Aprelikova O., Persico, M.G., Terman B. I. and Alitalo K. (1993). The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J. Exp. Med. 178, 2077-2088.
63. Karkkainen M.J., Alitalo K. and Makinen T. (2002). Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin. Cell Dev. Biol. 13, 9-18.
64. Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A., Levinson K.L., Mctigue M.A., Alitalo K. and Finegold D.N. (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25, 153-9.
65. Karkkainen M.J., Jussila L., Ferrell R.E., Finegold D.N. and Alitalo K. (2001). Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol. Med. 7, 18-22.
66. Karkkainen M.J., Makinen T. and Alitalo K. (2002b). Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol. 4, E2-5.
67. Karkkainen M.J. and Petrova T.V. (2000). Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19, 5598-605.
68. Karpanen T. and Alitalo K. (2001). Lymphatic vessels as targets of tumor therapy? J. Exper. Med. 194, F37-F42.
69. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M. and Alitalo K. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61, 1786-1790.
70. Kato S., Yasunaga A. and Uchida U. (1991). Enzyme-histochemical method for identification of lymphatic capillaries. Lymphology 24, 125-129.
71. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J. and Connolly D.T. (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309-1312.
72. Kitadai Y., Amioka T., Haruma K., Tanaka S., Yoshihara M., Sumii K., Matsutani N., Yasui W. and Chayama K. (2001). Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int. J. Cancer 93, 662-666.
73. Korpelainen E.I., Karkkainen M., Gunji Y., Vikkula M. and Alitalo K. (1999). Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 18, 1-8.
74. Kowalczyk A., Navarro P., Dejana E., Bornslaeger E., Green K., Kopp D. and Je B. (1998). VE-cadherin and desmoplakin are assembled into dermal microvascular endothelial intercellular junctions: a pivotal role for plakoglobin in the recruitment of desmoplakin to intercellular junctions. J. Cell Sci. 3045-3057.
75. Kubo H., Fujiwara T., Jussila L., Hashi H., Ogawa M., Shimizu K., Awane M., Sakai Y., Takabayashi A., Alitalo K., Yamaoka Y. and Nishikawa S. (2000). Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96, 546-553.
76. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V. and Alitalo K. (1996). VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122, 3829-37.
77. Kurebayashi J., Otsuki T., Kunisue H., Mikami Y., Tanaka K., Yamamoto S. and Sonoo H. (1999). Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Japanese J. Cancer Res. 90, 977-981.
78. Leak L.B.J. (1968). Ultrastructural studies on the lymphatic ancchoring filaments. J. Biol. Blol. 36, 129-149.
79. Lee J., Gray A., Yuan J., Luoh S., Avraham H. and Wood W. (1996). Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA. 93, 1988-1992.
80. Leu A.J., Berk D.A., Lymboussaki A., Alitalo, K. and Jain R.K. (2000). Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res. 60, 4324-4327.
81. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V. and Ferrara N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
82. Lymboussaki A., Olofsson B., Eriksson U. and Alitalo K. (1998). Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. Res. 85, 992-999.
83. Lymboussaki A., Olofsson B., Eriksson U. and Alitalo K. (1999). Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. Res. 85, 992-999.
84. Madri J., Sankar S. and Romanic A. (1996). Angiogenesis. In: The molecular and cellular biology of wound repair. 2nd ed. Clark R.A.F. led). Plenum Press. New York. pp 355-371.
85. Magari S. and Ito Y. (1988). Weible-Palade bodies in endothelial cells of normal thoracic ducts and deep cervical lymphatics in rabbits. Lymphology 21, 93-98.
86. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S.I., Yla-Herttuala S. and Alitalo K. (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199-205.
87. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., Orci L., Alitalo K., Christofori G. and Pepper M.S. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682.
88. Marchetti C., Poggi P., Calligaro A. and Casasco A. (1992). Lymphatic vessels of the human dental pulp in different conditions. Anat. Rec. 234, 27-33.
89. Marconcini L., Marchio S., Morbidelli L., Cartocci E., Albini A., Ziche M., Bussolino F. and Oliviero S. (1999). c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96, 9671-9676.
90. Matsui K., Breiteneder-Geleff S. and Kerjaschki D. (1998). Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J. Am. Soc. Nephrol. 9, 2013-2026.
91. Matsui K., Breiteneder-Geleff S., Soleiman A., Kowalski H. and Kerjaschki D. (1999). Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol. Dial. Transplant. 14, 9-11.
92. Mattila M.M., Ruohola J.K., Karpanen T., Jackson D.G., Alitalo K. and Harkonen P.L. (2002). VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 98, 946-951.
93. Maula S.M., Luukkaa M., Grenman R., Jackson D., Jalkanen S. and Ristamaki R. (2003). Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 63, 1920-1926.
94. Nagle R., Witte M., Martinez A., Witte C., Hendrix M., Way D. and Reed K. (1987). Factor VIII-associated antigen in human lymphatic endothelium. Lymphology 20, 20-24.
95. Niki T., Iba S., Tokunou M., Yamada T., Matsuno Y. and Hirohashi S. (2000). Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. CI Cancer Res. 6, 2431-2439.
96. Noguchi T., Takeno S., Shibata T., Uchida Y., Yokoyama S. and Muller W. (2002). VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol. Rep. 9, 995-999.
97. Nose K., Saito H. and Kuroki T. (1990). Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ. 1, 511-518.
98. Oh S., Jeltsch M., Birkenhager R., Mccarthy J., Weich H., Christ B., Alitalo K. and Wilting J. (1997). VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188, 96-109.
99. Ohta Y., Nozawa H., Tanaka Y., Oda M. and Watanabe Y. (2000). Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased NM23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thor. Cardiovas. Surg. 119, 804-813.
100. Ohta Y., Shridhar V., Bright R.K., Kalemkerian G.P., Du W., Carbone M., Watanabe Y. and Pass H.I. (1999). VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 81, 54-61.
101. Oliver G. and Detmar M. (2002). The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 16, 773-783.
102. Oliver G., Sosapineda B., Geisendorf S., Spana E.P., Doe C.Q. and Gruss P. (1993). Prox-1, a prospero-related homeobox gene expressed during mouse development. Mech. Dev. 44, 3-16.
103. Olofsson B., Jeltsch M., Eriksson U. and Alitalo K. (1999). Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 10, 528-535.
104. Orlandini M., Marconcini L., Ferruzzi R. and Oliviero S. (1996). Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endotheliall growth factor family. Proc. Natl. Acad. Sci. USA 93, 11675-11680.
105. Otsuki Y., Kubo H. and Magari S. (1990). Immunohistochemical differentiation between lymphatic vessels and blood vessels-use of antibasement membrane antibodies and anti-factor VIII-related antigen. Arch. Histol. Cytol. 53 Suppl., 95-105.
106. Paavonen K., Puolakkainen P., Jussila L., Jahkola T. and Alitalo K. (2000). Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156, 1499-1504.
107. Pajusola K., Aprelikova O., Armstrong E., Morris S. and Alitalo K. (1993). Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 8, 2931-2937.
108. Pajusola K., Aprelikova O., Pelicci G., Weich H., Claesson-Welsh L. and Alitalo K. (1994). Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 9, 3545-3555.
109. Paku S. and Paweletz N. (1991). First steps of tumor-related angiogenesis. Lab. Invest. 65, 334-346.
110. Parkin D.M. and Muir C.S. (1992). Cancer Incidence in Five Continents. Comparability and quality of data. IARC. Sci. Publ. 120, 46-173.
111. Parr C. and Jiang W.G. (2003). Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int. J. Oncol. 23, 533-539.
112. Partanen T., Alitalo K. and Miettinen M. (1999). Lack of lymphatic vascular specificity of vascular endotheliall growth factor receptor 3 in 185 vascular tumors. Cancer Res. 86, 2406-2412.
113. Partanen T.A., Arola J., Saaristo A., Jussila L., Ora A., Miettinen M., Stacker S.A., Achen M.G. and Alitalo K. (2000). VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 14, 2087-2096.
114. Pepper M.S. (2001). Lymphangiogenesis and tumor metastasis: Myth or reality? CI Cancer Res. 7, 462-468.
115. Picker L.J., Nakache M. and Butcher E.C. (1989). Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J. Cell Biol. 109, 927-937.
116. Rishi A., Joyce-Brady M., Fisher J., Dobbs L., Floros J., Vander Spek J., Brody J. and Williams M. (1995). Cloning, characterization, and development expression of a rat lung alveolar type I cell gene inembryonic endodermal and neural derivatives. Dev. Biol. 167, 294-306.
117. Ruiter D., Schlingemann R., Westphal J., Denijn M., Rietveld F. and De Waal R. (1993). Angiogenesis in wound healing and tumor metastasis. Behring Inst. Mitt. 92, 258-272.
118. Ryan T.J. (1989). Structure and function of lymphatics. J. Invest. Dermatol. 93 ( 2 Suppl.), 18S-24S.
119. Sabin F.R. (1902). On the origin of the lymphatic system from the veins and the development of lymph hearts and thoracic duct in the pig. Am. J. Anat. 1, 367-391.
120. Sabin F.R. (1904). On the development of the superficial lymphatics in the skin of pig. Am. J. Anat. 9, 43-91.
121. Sauter B., Foedinger D., Sterniczky B., Wolff K. and Rappersberger K. (1998). Immuneelectron microscopic characterization of human lymphatic microvascular endothelial cells. Differential expression of CD31, CD34 and type VI collagene with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma and haemangioma in-situ. J. Histochem. Cytochem. 46, 165-176.
122. Sawa Y., Shibata K., Braithwaite M., Suzuki M. and Yoshida S. (1999). Expression of immunoglobulin superfamily members on the lymphatic endothelium of inflamed human small intestine. Microvasc. 57, 100-106.
123. Schlingemann R., Hofman P., Anderson L., Troost D. and Van Der Gaag R. (1997). Vascular expression of endothelial antigen PAL-E indicates absence of blood-ocular barriers in the normal eye. Ophthalmic. Res. 29, 130-138.
124. Schmelz M., Moll R., Kuhn C. and Franke W.W. (1994b). Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: II. Different types of lymphatic vessels. Differentiation 57, 97-117.
125. Schneider M., Othman-Hassan K., Christ B. and Wilting J. (1999). Lymphangioblasts in the avian wing bud. Dev. Dyn. 216, 311-319.
126. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K. and Detmar M. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192-198.
127. Slack N.H., Lane W.W., Priore R.L. and Murphy G.P. (1986). Prostatic cancer. Treated at a categorical center, 1980-1983. Urology 27, 205-213.
128. Sleeman J.P. (2000). The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 157, 55-81.
129. Sleeman J.P., Krishnan J., Kirkin V. and Baumann P. (2001). Markers for the lymphatic endothelium: In search of the holy grail? Microsc. Res. Tech. 55, 61-69.
130. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B. and Kinzler K.W. (2000). Genes expressed in human tumor endothelium. Science 289, 1197-202.
131. Stacker S., Caeser C., Baldwin M., Thornton G., Williams R., Prevo R., Jackson D., Nishikawa S., Kubo H. and Achen M. (2001). VEGF-D promots the metastatic spreadof tumour cells via the lymphatics. Nat. Med., 7, 186-191.
132. Stanley K., Stjernsward J. and Koroltchouk V. (1988). Cancers of the stomach, lung and breast: mortality trends and control strategies. World Health Stat Q. 41, 107-114.
133. Takahashi A., Kono K., Itakura J., Amemiya H., Feng Tang R., Iizuka H., Fujii H. and Matsumoto Y. (2002). Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 62, 121-127.
134. Tanigawa N., Kanazawa T., Satomura K., Hikasa Y., Hashida M., Muranishi S. and Sezaki H. (1981). Experimental-study on lymphatic vascular changes in the development of cancer. Lymphology 14, 149-154.
135. Tomarev S.I., Sundin O., Banerjeebasu S., Duncan M.K., Yang J.M. and Piatigorsky J. (1996). Chicken homeobox gene Prox 1 related to Drosophila prospero is expressed in the developing lens and retina. Dev. Dyn. 206, 354-367.
136. Tsurusaki T., Kanda S., Sakai H., Kanetake H., Saito Y., Alitalo K. and Koji T. (1999). Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J Cancer. 80, 309-313.
137. Valiron O., Chevrier V., Usson Y., Breviario F., Job D. and Dejana E. (1996). Desmoplakin expression and organization at human umbilical vein endothelial cell-to-cell junctions. J. Cell. Sci. 109 (pt 8), 2141-2149.
138. Valtola R., Salven P., Heikkila P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., Dewaal R. and Alitalo K. (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154, 1381-1390.
139. Van Trappen P.O. and Pepper M.S. (2001). Lymphangiogenesis and lymph node microdissemination. Gynecol. Oncol. 82, 1-3.
140. Veikkola T., Karkkainen M., Claesson-Welsh L. and Alitalo K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60, 203-212.
141. Wang J.F., Ganju R.K., Liu Z.Y., Avraham H., Avraham S. and Groopman J.E. (1997). Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor. Blood 90, 3507-3515.
142. Weber E., Lorenzoni P., Lozzi G. and Sacchi G. (1994). Cytochemical differentiation between blood and lymphatic endothelium: bovine blood and lymphatic large vessels and endothelial cells in culture. J. Histochem. Cytochem. 42, 1109-1115.
143. Weidner N. (1995). Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9-19.
144. Weninger W., Partanen T.A., Breiteneder-Geleff S., Mayer C., Kowalski H., Mildner M., Pammer J., Sturzl M., Kerjaschki D., Alitalo K. and Tschachler E. (1999). Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab. Invest. 79, 243-251.
145. Werner J., Schunke M. and Tillmann B. (1987). Histochemical visualization of lymphatic capillaries in the rat: a comparison of methods demonstrated at the posterior pharyngeal surface. Arch. Histol. Jpn. 50, 505-514.
146. Wetterwald A., Hoffstetter W., Cecchini M., Lanske B., Wagner C., Fleisch H. and Atkinson M. (1996). Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 125-132.
147. White J.D., Hewett P.W., Kosuge D., Mcculloch T., Enholm B.C., Carmichael J. and Murray J.C. (2002). Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62, 1669-1675.
148. Wigle J. and Oliver G. (1999). Prox-1 function is required for the development of the murine lymphatic system. Cell 98, 769-778.
149. Williams C.S., Leek R.D., Robson A.M., Banerji S., Prevo R., Harris A.L. and Jackson D.G. (2003). Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol. 200, 195-206.
150. Wilting J., Neeff H. and Christ B. (1999). Embryonic lymphangiogenesis. Cell Tissue Res. 297, 1-11.
151. Witte M.H., Way D.L., Witte C.L. and Bernas M. (1997). Lymphangiogenesis: mechanisms, significance and clinical implications. EXS. 79, 65-112.
152. Witte M.H., Erickson R., Bernas M., Andrade M., Reiser F, Conlon W., Hoyme H.E. and Witte C.L. (1998). Phenotypic and genotypic heterogeneity in familial Milroy lymphedema. Lymphology 31, 145-155.
153. Witte M.H., Bernas M.J., Martin C.P. and Witte C.L. (2001). Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc. Res. Tech. 55, 122-145.
154. Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J.S. and Isner J. M. (1998). Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, 381-394.
155. Xia P., Aiello L.P., Ishii H., Jiang Z.Y., Park D.J., Robinson G.S., Takagi H., Newsome W.P., Jirousek M.R. and King G.L. (1996). Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018-2026.
156. Yamada Y., Nezu J., Shimane M. and Hirata Y. (1997). Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42, 483-488.
157. Yonemura Y., Endo Y., Fujita H., Fushida S., Ninomiya I., Bandou E., Taniguchi K., Miwa K., Ohoyama S., Sugiyama K. and Sasaki T. (1999). Role of vascular endothelial growth factor C express ion in the
158. Yonemura Y., Fushida S., Bando E., Kinoshita K., Miwa K., Endo Y., Sugiyama K., Partanen T., Yamamoto H. and Sasaki T. (2001). Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur. J. Cancer 37, 918-923.
159. Yoshizawa M., Shingaki S., Nakajima T. and Saku T. (1994). Histopathological study of lymphatic invasion in squamous cell carcinoma (O-1N) with high potential of lymph node metastasis. Clin. Exp. Metastasis 12, 347-356.
160. Zimmermann S. and Moelling K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741-1744.
161. Zoellner H. and Hunter N. (1989). Histochemical identification of the vascular endothelial isoenzyme of alkaline phosphatase. J. Histochem. Cytochem. 37, 1893-1898.